Connection

Francis Spinale to Humans

This is a "connection" page, showing publications Francis Spinale has written about Humans.
Connection Strength

1.213
  1. Cytokine Signaling and Matrix Remodeling Pathways Associated with Cardiac Sarcoidosis Disease Activity Defined Using FDG PET Imaging. Int Heart J. 2021 Sep 30; 62(5):1096-1105.
    View in: PubMed
    Score: 0.030
  2. Targeted Injection of a Truncated Form of Tissue Inhibitor of Metalloproteinase 3 Alters Post-Myocardial Infarction Remodeling. J Pharmacol Exp Ther. 2020 11; 375(2):296-307.
    View in: PubMed
    Score: 0.028
  3. Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation. J Card Fail. 2020 Oct; 26(10):876-884.
    View in: PubMed
    Score: 0.027
  4. Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype. Nat Rev Cardiol. 2020 08; 17(8):523-531.
    View in: PubMed
    Score: 0.026
  5. Common pathways and communication between the brain and heart: connecting post-traumatic stress disorder and heart failure. Stress. 2019 09; 22(5):530-547.
    View in: PubMed
    Score: 0.025
  6. Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review. JAMA Cardiol. 2018 12 01; 3(12):1232-1243.
    View in: PubMed
    Score: 0.024
  7. Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm. 2019 05; 16(5):743-753.
    View in: PubMed
    Score: 0.024
  8. Identification of a novel microRNA profile in pediatric patients with cancer treated with anthracycline chemotherapy. Am J Physiol Heart Circ Physiol. 2018 11 01; 315(5):H1443-H1452.
    View in: PubMed
    Score: 0.024
  9. Cardiovascular Risk and Matrix Metalloproteinase Polymorphisms: Not Just a Simple Substitution. Circ Cardiovasc Genet. 2017 12; 10(6):e001958.
    View in: PubMed
    Score: 0.023
  10. In vivo assessment of regional mechanics post-myocardial infarction: A focus on the road ahead. J Appl Physiol (1985). 2017 Oct 01; 123(4):728-745.
    View in: PubMed
    Score: 0.022
  11. Crossing Into the Next Frontier of Cardiac Extracellular Matrix Research. Circ Res. 2016 10 28; 119(10):1040-1045.
    View in: PubMed
    Score: 0.021
  12. Improving Delivery of a Biomaterial Payload in Myocardial Infarction. Circ Cardiovasc Interv. 2016 10; 9(10).
    View in: PubMed
    Score: 0.021
  13. Assessment of Cardiac Function--Basic Principles and Approaches. Compr Physiol. 2015 Sep 20; 5(4):1911-46.
    View in: PubMed
    Score: 0.020
  14. Fate Versus Flow: Wall Shear Stress in the Aortopathy Associated With Bicuspid Aortic Valves. J Am Coll Cardiol. 2015 Aug 25; 66(8):901-4.
    View in: PubMed
    Score: 0.019
  15. Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy. Am J Physiol Heart Circ Physiol. 2014 Sep 01; 307(5):H752-61.
    View in: PubMed
    Score: 0.018
  16. Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol. 2014 Jul 01; 90(1):7-15.
    View in: PubMed
    Score: 0.018
  17. Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice. Circ Res. 2014 Apr 25; 114(9):1435-45.
    View in: PubMed
    Score: 0.018
  18. Myocardial fibroblast-matrix interactions and potential therapeutic targets. J Mol Cell Cardiol. 2014 May; 70:92-9.
    View in: PubMed
    Score: 0.017
  19. Integrating the myocardial matrix into heart failure recognition and management. Circ Res. 2013 Aug 30; 113(6):725-38.
    View in: PubMed
    Score: 0.017
  20. Preoperative steroid treatment does not improve markers of inflammation after cardiac surgery in neonates: results from a randomized trial. J Thorac Cardiovasc Surg. 2014 Mar; 147(3):902-8.
    View in: PubMed
    Score: 0.017
  21. Localized targeting of biomaterials following myocardial infarction: a foundation to build on. Trends Cardiovasc Med. 2013 Nov; 23(8):301-11.
    View in: PubMed
    Score: 0.017
  22. Biomarkers and heart disease: what is translational success? J Cardiovasc Transl Res. 2013 Aug; 6(4):447-8.
    View in: PubMed
    Score: 0.017
  23. Membrane-associated matrix proteolysis and heart failure. Circ Res. 2013 Jan 04; 112(1):195-208.
    View in: PubMed
    Score: 0.016
  24. Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol. 2013 Mar 01; 304(5):C393-402.
    View in: PubMed
    Score: 0.016
  25. Differential membrane type 1 matrix metalloproteinase substrate processing with ischemia-reperfusion: relationship to interstitial microRNA dynamics and myocardial function. J Thorac Cardiovasc Surg. 2013 Jan; 145(1):267-275, 277.e1-4; discussion 275-7.
    View in: PubMed
    Score: 0.016
  26. Gene targeting in ischemic heart disease and failure: translational and clinical studies. Biochem Pharmacol. 2013 Jan 01; 85(1):1-11.
    View in: PubMed
    Score: 0.016
  27. Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. J Card Fail. 2012 Jun; 18(6):487-92.
    View in: PubMed
    Score: 0.016
  28. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol. 2012 Apr 01; 302(7):H1429-37.
    View in: PubMed
    Score: 0.015
  29. Changes in the myocardial interstitium and contribution to the progression of heart failure. Heart Fail Clin. 2012 Jan; 8(1):7-20.
    View in: PubMed
    Score: 0.015
  30. Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2012 May; 143(5):1069-76.
    View in: PubMed
    Score: 0.015
  31. Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet. 2011 Dec; 4(6):614-9.
    View in: PubMed
    Score: 0.015
  32. Early postoperative outcomes and blood product utilization in adult cardiac surgery: the post-aprotinin era. Circulation. 2011 Sep 13; 124(11 Suppl):S62-9.
    View in: PubMed
    Score: 0.015
  33. Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J Thorac Cardiovasc Surg. 2012 Mar; 143(3):656-64.
    View in: PubMed
    Score: 0.015
  34. Standardized preoperative corticosteroid treatment in neonates undergoing cardiac surgery: results from a randomized trial. J Thorac Cardiovasc Surg. 2011 Dec; 142(6):1523-9.
    View in: PubMed
    Score: 0.014
  35. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail. 2011 May; 4(3):246-56.
    View in: PubMed
    Score: 0.014
  36. Myocardial remodeling: cellular and extracellular events and targets. Annu Rev Physiol. 2011; 73:47-68.
    View in: PubMed
    Score: 0.014
  37. Determinants of extracellular matrix remodelling are differentially expressed in paediatric and adult dilated cardiomyopathy. Eur J Heart Fail. 2011 Mar; 13(3):271-7.
    View in: PubMed
    Score: 0.014
  38. Plasma profiling determinants of matrix homeostasis in paediatric dilated cardiomyopathy. Cardiol Young. 2011 Feb; 21(1):52-61.
    View in: PubMed
    Score: 0.014
  39. Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. J Biol Chem. 2010 Sep 24; 285(39):30316-27.
    View in: PubMed
    Score: 0.014
  40. Amplified bioactive signaling and proteolytic enzymes following ischemia reperfusion and aging: remodeling pathways that are not like a fine wine. Circulation. 2010 Jul 27; 122(4):322-4.
    View in: PubMed
    Score: 0.014
  41. Circulating matrix metalloproteinase levels after ventricular septal defect repair in infants. J Thorac Cardiovasc Surg. 2010 Dec; 140(6):1257-65.
    View in: PubMed
    Score: 0.014
  42. Effects of aprotinin or tranexamic acid on proteolytic/cytokine profiles in infants after cardiac surgery. Ann Thorac Surg. 2010 Jun; 89(6):1843-52; discussion 1852.
    View in: PubMed
    Score: 0.014
  43. Pathophysiology of myocardial injury and remodeling: implications for molecular imaging. J Nucl Med. 2010 May 01; 51 Suppl 1:102S-106S.
    View in: PubMed
    Score: 0.013
  44. Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics. J Thorac Cardiovasc Surg. 2010 Mar; 139(3):646-54.
    View in: PubMed
    Score: 0.013
  45. Cardiac-restricted overexpression of membrane type-1 matrix metalloproteinase in mice: effects on myocardial remodeling with aging. Circ Heart Fail. 2009 Jul; 2(4):351-60.
    View in: PubMed
    Score: 0.013
  46. Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail. 2009 May; 2(3):262-71.
    View in: PubMed
    Score: 0.013
  47. Endothelin-A receptor inhibition after cardiopulmonary bypass: cytokines and receptor activation. Ann Thorac Surg. 2008 Nov; 86(5):1576-83.
    View in: PubMed
    Score: 0.012
  48. Dynamic changes in matrix metalloprotienase activity within the human myocardial interstitium during myocardial arrest and reperfusion. Circulation. 2008 Sep 30; 118(14 Suppl):S16-23.
    View in: PubMed
    Score: 0.012
  49. Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice. Am J Physiol Heart Circ Physiol. 2008 Oct; 295(4):H1394-402.
    View in: PubMed
    Score: 0.012
  50. Differential effects of epsilon-aminocaproic acid and aprotinin on matrix metalloproteinase release in patients following cardiopulmonary bypass. J Cardiovasc Pharmacol. 2008 Apr; 51(4):418-23.
    View in: PubMed
    Score: 0.012
  51. Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth Analg. 2007 Oct; 105(4):949-62.
    View in: PubMed
    Score: 0.011
  52. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007 Oct; 87(4):1285-342.
    View in: PubMed
    Score: 0.011
  53. Membrane-type-1 matrix metalloproteinase transcription and translation in myocardial fibroblasts from patients with normal left ventricular function and from patients with cardiomyopathy. Am J Physiol Cell Physiol. 2007 Oct; 293(4):C1362-73.
    View in: PubMed
    Score: 0.011
  54. Selective endothelin-A receptor inhibition after cardiac surgery: a safety and feasibility study. Ann Thorac Surg. 2007 Jun; 83(6):2153-60; discussion 2161.
    View in: PubMed
    Score: 0.011
  55. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation. 2006 Sep 05; 114(10):1020-7.
    View in: PubMed
    Score: 0.010
  56. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg. 2006 Mar; 131(3):679-85.
    View in: PubMed
    Score: 0.010
  57. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res. 2006 Feb 15; 69(3):666-76.
    View in: PubMed
    Score: 0.010
  58. From tadpole tails to transgenic mice: metalloproteinases have brought about a metamorphosis in our understanding of cardiovascular disease. Cardiovasc Res. 2006 Feb 15; 69(3):559-61.
    View in: PubMed
    Score: 0.010
  59. Matrix modulation and heart failure: new concepts question old beliefs. Curr Opin Cardiol. 2005 May; 20(3):211-6.
    View in: PubMed
    Score: 0.010
  60. Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail. 2005 Mar; 11(2):124-30.
    View in: PubMed
    Score: 0.009
  61. Dynamic and differential changes in myocardial and plasma endothelin in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005 Mar; 129(3):584-90.
    View in: PubMed
    Score: 0.009
  62. Disruptions and detours in the myocardial matrix highway and heart failure. Curr Heart Fail Rep. 2005 Mar; 2(1):10-7.
    View in: PubMed
    Score: 0.009
  63. Cell-matrix signaling and thrombospondin: another link to myocardial matrix remodeling. Circ Res. 2004 Sep 03; 95(5):446-8.
    View in: PubMed
    Score: 0.009
  64. The effects of leukocyte reduction on matrix metalloproteinase release in cardiopulmonary bypass. J Extra Corpor Technol. 2004 Jun; 36(2):185-90.
    View in: PubMed
    Score: 0.009
  65. Myocyte contractility with caspase inhibition and simulated hyperkalemic cardioplegic arrest. Ann Thorac Surg. 2004 May; 77(5):1684-9; discussion 1689-90.
    View in: PubMed
    Score: 0.009
  66. Matrix metalloproteinase gene polymorphisms in heart failure: new pieces to the myocardial matrix puzzle. Eur Heart J. 2004 Apr; 25(8):631-3.
    View in: PubMed
    Score: 0.009
  67. A prospective, randomized study of endothelin and postoperative recovery in off-pump versus conventional coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 2004 Feb; 18(1):25-9.
    View in: PubMed
    Score: 0.009
  68. Effects of leukocyte depletion filters on matrix metalloproteinase activation in an extracorporeal circulation circuit. J Extra Corpor Technol. 2003 Jun; 35(2):139-42.
    View in: PubMed
    Score: 0.008
  69. Matrix metalloproteinase abundance in human myocardial fibroblasts: effects of sustained pharmacologic matrix metalloproteinase inhibition. J Mol Cell Cardiol. 2003 May; 35(5):539-48.
    View in: PubMed
    Score: 0.008
  70. Extracellular matrix remodeling following myocardial injury. Ann Med. 2003; 35(5):316-26.
    View in: PubMed
    Score: 0.008
  71. Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2002 Dec 18; 40(12):2165-73.
    View in: PubMed
    Score: 0.008
  72. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail. 2002 Dec; 8(6):390-8.
    View in: PubMed
    Score: 0.008
  73. Extracellular degradative pathways in myocardial remodeling and progression to heart failure. J Card Fail. 2002 Dec; 8(6 Suppl):S332-8.
    View in: PubMed
    Score: 0.008
  74. The extracellular matrix: summation. J Card Fail. 2002 Dec; 8(6 Suppl):S349-50.
    View in: PubMed
    Score: 0.008
  75. Interpretable machine learning predicts cardiac resynchronization therapy responses from personalized biochemical and biomechanical features. BMC Med Inform Decis Mak. 2022 10 31; 22(1):282.
    View in: PubMed
    Score: 0.008
  76. Effects of adrenomedullin on human myocyte contractile function and beta-adrenergic response. J Cardiovasc Pharmacol Ther. 2002 Oct; 7(4):235-40.
    View in: PubMed
    Score: 0.008
  77. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002 Mar 22; 90(5):520-30.
    View in: PubMed
    Score: 0.008
  78. Ensemble machine learning model identifies patients with HFpEF from matrix-related plasma biomarkers. Am J Physiol Heart Circ Physiol. 2022 05 01; 322(5):H798-H805.
    View in: PubMed
    Score: 0.008
  79. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res. 2002 Mar; 53(4):822-30.
    View in: PubMed
    Score: 0.008
  80. The Effects of Regular Exercise on Circulating Cardiovascular-related MicroRNAs. Sci Rep. 2019 05 17; 9(1):7527.
    View in: PubMed
    Score: 0.006
  81. Plasma matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs and aging and lifelong exercise adaptations in ventricular and arterial stiffness. Exp Gerontol. 2019 08; 123:36-44.
    View in: PubMed
    Score: 0.006
  82. Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition. Nat Mater. 2014 Jun; 13(6):653-61.
    View in: PubMed
    Score: 0.004
  83. Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion. J Cardiovasc Transl Res. 2013 Aug; 6(4):528-35.
    View in: PubMed
    Score: 0.004
  84. Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase. Pflugers Arch. 2013 May; 465(5):687-97.
    View in: PubMed
    Score: 0.004
  85. Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res. 2012 Jun 22; 111(1):131-50.
    View in: PubMed
    Score: 0.004
  86. Aortic dilatation with bicuspid aortic valves: cusp fusion correlates to matrix metalloproteinases and inhibitors. Ann Thorac Surg. 2012 Feb; 93(2):457-63.
    View in: PubMed
    Score: 0.004
  87. Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. Circ Cardiovasc Genet. 2011 Dec; 4(6):605-13.
    View in: PubMed
    Score: 0.004
  88. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010 Dec 21; 122(25):2660-8.
    View in: PubMed
    Score: 0.003
  89. Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium. Histochem Cell Biol. 2010 Jul; 134(1):23-30.
    View in: PubMed
    Score: 0.003
  90. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation. 2010 May 04; 121(17):1912-25.
    View in: PubMed
    Score: 0.003
  91. Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung. J Thorac Cardiovasc Surg. 2010 Apr; 139(4):984-90; discussion 990.
    View in: PubMed
    Score: 0.003
  92. SmartDelay determined AV optimization: a comparison of AV delay methods used in cardiac resynchronization therapy (SMART-AV): rationale and design. Pacing Clin Electrophysiol. 2010 Jan; 33(1):54-63.
    View in: PubMed
    Score: 0.003
  93. Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. J Vasc Res. 2009; 46(2):119-37.
    View in: PubMed
    Score: 0.003
  94. Regional heterogeneity within the aorta: relevance to aneurysm disease. J Thorac Cardiovasc Surg. 2008 Nov; 136(5):1123-30.
    View in: PubMed
    Score: 0.003
  95. Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. Eur J Heart Fail. 2008 Feb; 10(2):125-8.
    View in: PubMed
    Score: 0.003
  96. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail. 2007 Sep; 13(7):530-40.
    View in: PubMed
    Score: 0.003
  97. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg. 2007 Apr; 133(4):1028-36.
    View in: PubMed
    Score: 0.003
  98. Proteinase systems and thoracic aortic aneurysm progression. J Surg Res. 2007 May 15; 139(2):292-307.
    View in: PubMed
    Score: 0.003
  99. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation. 2006 Jul 04; 114(1 Suppl):I365-70.
    View in: PubMed
    Score: 0.003
  100. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006 May 02; 113(17):2089-96.
    View in: PubMed
    Score: 0.003
  101. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006 Feb 15; 97(4):532-7.
    View in: PubMed
    Score: 0.002
  102. Left ventricular form and function: scientific priorities and strategic planning for development of new views of disease. Circulation. 2004 Oct 05; 110(14):e333-6.
    View in: PubMed
    Score: 0.002
  103. Duality of innate stress responses in cardiac injury, repair, and remodeling. J Mol Cell Cardiol. 2004 Oct; 37(4):801-11.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.